Edgewise Therapeutics, Inc.
corporate_fare Company Profile
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 12 items for EWTX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-06, rated 8/10. Across its 12 most recent items scored 7 or higher, the top rating is 10/10, with 8 rated 8 or above. Recent SEC coverage for EWTX spans 10-Q, 8-K, 8-K/A, 10-K.
Recent high-impact activity:
- Edgewise Jumps 12% on Report of Takeover Interest and Adviser-Led Sales Process
- Edgewise Swings to $1.17B Profit on Sevasemten Sale, $1.74B Cash, Phase 3 HCM Trial by Year-End
- Edgewise Q2 2026: $460.7M cash before Sevasemten close; $1.55B upfront received July 10; EDG-7500 Phase 3 on track for Q4
- Edgewise Delivers Positive Phase 2 HCM Data and Q2 Results; Pro Forma Cash Hits $2B After Servier Deal
- Edgewise Files Pro Forma Financials for $1.55B Sevasemten Sale to Servier
Financial Snapshot
Short Interest & Short Volume
9.64 days to coverFINRA reported short interest of 12,696,203 shares in EWTX as of the October 30, 2026 settlement, a 8.0% increase from the prior period — about 9.6 days to cover at its recent average daily volume. On November 20, 2026, 41.9% of EWTX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.